- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07775235
Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease
Assessment of Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The primary feature of idiopathic inflammatory myopathies (IIM) is inflammation of muscles, yet extra-muscular manifestations are common such as interstitial lung disease (ILD). Based on both muscular and extra-muscular features, patients can fall into different types of IIMs, including broad subtypes of dermatomyositis (DM), polymyositis (PM), inclusion-body myositis (IBM) and immune-mediating necrotizing myopathies (IMNM). Particular subtypes such as dermatomyositis patients positive for anti-melanoma differentiation-associated protein 5 (anti-MDA5) are most commonly associated with rapidly progressive lung involvement and high mortality, with survival at 1 year being less than 60% despite current available treatment. Treatment for IIM patients involves immunosuppression, though there is no consensus or treatment guidelines available for different subtypes, particularly for myositis-associated RP-ILD. Despite several trials having shown increased efficacy with more aggressive immunosuppressive regimes, mortality still remains high. There is thus an unmet need with regards to treatment of patients with IIM, particularly for myositis-associated RP-ILD.
There is an urgent need to improve outcomes in myositis-associated RP-ILD. Till date, there are no randomised controlled trials that investigate therapy of myositis-associated RP-ILD likely due to the low incidence of the disease. Current best level of evidence for therapies come from single-arm prospective cohort studies with comparison with historical controls. Recent studies using combination therapy to target different aspects of these pathological processes have demonstrated increased efficacy compared to single target alone. This shows that appropriate selection of targets with subsequent combination blockade will be beneficial in treatment of patients with myositis associated RP-ILD. Hence, the investigators propose the utilization of rituximab to block the B-cell involvement, tacrolimus to target T-cells, tofacitinib to block interferon signaling with steroids due to their effects on both the innate and adaptive system in the treatment of myositis-associated RP-ILD. Such combination therapy allows precise targeting of pathways responsible for pathophysiology of the disease, without high individual dosages and hence reducing potential side effects. Till date there are no prospective studies that look into current combination of steroids, tacrolimus, tofacitinib and rituximab in the patients with myositis-associated RP-ILD. However, a drawback for increased immunosuppression is infection, particularly with cytomegalovirus (CMV). The investigators will employ a prophylactic treatment strategy to mitigate the risk of increased infection following higher intensity immunosuppression.
The primary end point will be survival rate at 6 months from initiation of treatment.
Secondary end points include improvement of clinical status, biochemical markers, radiological appearance and parameters on lung function test. Secondary end points also include adverse events rate including side effects from treatment and infection rates.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Mohamad Fadhli Bin Masri, MD PhD
- Telefonnummer: 6576 2609
- E-post: mohamad.fadhli@mohh.com.sg
Studieorter
-
-
-
Singapore, Singapore
- Rekrytering
- Singapore General Hospital
-
Kontakt:
- Mohamad Fadhli Bin Masri, MD PhD
- Telefonnummer: 6576 2609
- E-post: mohamad.fadhli@mohh.com.sg
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Age of 21 years or above;
- Diagnosis of myositis associated rapidly progressive interstitial lung disease
Exclusion Criteria:
- Age of less than 21 year old;
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Treatment group
Patients with immune-mediated myositis-associated rapidly progressive interstitial lung disease undergoing treatment with combined immunosuppressive treatment
|
Combination treatment regimen lasting 6 months with A) Steroids: Starting with Intravenous methylprednisolone (500mg once daily for three days) followed by tapering dose of prednisolone B) Rituximab (1000mg given at the start of treatment and 1000mg 2 weeks after the first dose) C) Tacrolimus D) Tofacitinib
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
All-cause mortality at 6 months from treatment initiation
Tidsram: 6 months
|
Proportion of total participants who demise from all cause till 6 months from treatment initiation (percentage of all participants)
|
6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in clinical status through Modified Medical Research Council Dyspnea Scale
Tidsram: 6 months
|
The Modified Medical Research Council (mMRC) Dyspnea Scale will be used to rate participants' functional status at start of treatment and at 6 months post treatment (0 to 4).
|
6 months
|
|
Change in clinical status through requirement of supplemental oxygen at 6 months
Tidsram: 6 months
|
Proportion of participants who require oxygen supplementation at the start of treatment and 6 months post treatment (percentage of all participants).
|
6 months
|
|
Safety of treatment regimen in participants
Tidsram: 6 months
|
Number of adverse infection events experienced by participants
|
6 months
|
|
Safety of treatment regimen in participants
Tidsram: 6 months
|
Number of adverse haematological events leading to change of medication as per managing physician
|
6 months
|
|
Safety of treatment regimen in participants
Tidsram: 6 months
|
Number of adverse biochemical events leading to change of medication as per managing physician
|
6 months
|
|
Change in biochemical markers of disease activity
Tidsram: 1 year
|
Levels of C-reactive protein (mg/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year
|
1 year
|
|
Change in biochemical markers of disease activity
Tidsram: 1 year
|
Levels of Erythrocyte sedimentation rate (mm/h) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
|
1 year
|
|
Change in biochemical markers of disease activity
Tidsram: 1 year
|
Levels of Ferritin (ug/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
|
1 year
|
|
Change in biochemical markers of disease activity
Tidsram: 1 year
|
Levels of Lactate dehydrogenase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
|
1 year
|
|
Change in biochemical markers of disease activity
Tidsram: 1 year
|
Levels of Creatine kinase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
|
1 year
|
|
Change in biochemical markers of disease activity
Tidsram: 1 year
|
Levels of Aldolase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
|
1 year
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Muskuloskeletala sjukdomar
- Sjukdomar i nervsystemet
- Muskelsjukdomar
- Neuromuskulära sjukdomar
- Luftvägssjukdomar
- Lungsjukdomar
- Lungsjukdomar, interstitiell
- Myosit
- Aminosyror, peptider och proteiner
- Proteiner
- Organiska kemikalier
- Polycykliska föreningar
- Antikroppar, monoklonal
- Antikroppar
- Immunglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Graviditet
- Graviditet
- Steroider
- Fusion-ringföreningar
- Makrolider
- Laktoner
- Graviditet
- Antikroppar, monoklonal, murin härledd
- Rituximab
- Prednisolon
- Takrolimus
- tofacitinib
Andra studie-ID-nummer
- 2024/2307
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .